Top

Published in:

01-12-2008 | Viewpoint

Osteopontin: a new role for a familiar actor

Authors: Nicholas IF Johnston, Mohamed K El-Tanani

Published in: Breast Cancer Research | Issue 6/2008

Abstract

Our understanding of the events that occur in cancer progression has been enhanced by the use of cell lines in vitro. Changes in gene expression, induction of signalling, and cell motility can all be investigated in this setting. However, other aspects of progression can be revealed only in vivo, especially the interactions of tumour cells with host cells and organ systems. In one such in vivo model, described by McAllister and colleagues, it proved possible to establish a novel function of an already well-characterised protein, osteopontin, adding to its attractiveness as a target in cancer therapy.

Alizadeh AA, Ross DT, Perou CM, Rijn van de M: Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001, 195: 41-52. 10.1002/path.889.CrossRefPubMed

McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA: Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008, 133: 994-1005. 10.1016/j.cell.2008.04.045.CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed

Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF: Osteopontin induces multiple changes in gene expression that reflect the six 'hallmarks of cancer' in a model of breast cancer progression. Mol Carcinog. 2005, 43: 225-236. 10.1002/mc.20105.CrossRefPubMed

El-Tanani MK: Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci. 2008, 13: 4276-4284. 10.2741/3004.CrossRefPubMed

Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H: The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16: 1087-1097. 10.1158/1055-9965.EPI-06-1008.CrossRefPubMed

Desai B, Rogers MJ, Chellaiah MA: Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer. 2007, 6: 18-10.1186/1476-4598-6-18.CrossRefPubMedPubMedCentral

Sodek J, Ganss B, McKee MD: Osteopontin. Crit Rev Oral Biol Med. 2000, 11: 279-303. 10.1177/10454411000110030101.CrossRefPubMed

He B, Mirza M, Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006, 25: 2192-2202. 10.1038/sj.onc.1209248.CrossRefPubMed

10.

Shinohara ML, Kim HJ, Kim JH, Garcia VA, Cantor H: Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci USA. 2008, 105: 7235-7239. 10.1073/pnas.0802301105.CrossRefPubMedPubMedCentral

11.

Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM: Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res. 2007, 67: 5141-5147. 10.1158/0008-5472.CAN-06-4763.CrossRefPubMed

12.

Tuck AB, Chambers AF, Allan AL: Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 2007, 102: 859-868. 10.1002/jcb.21520.CrossRefPubMed

13.

Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK: Osteopontin as a target for cancer therapy. Front Biosci. 2008, 13: 4361-4372. 10.2741/3009.CrossRefPubMed

14.

Kurisetty VV, Johnston PG, Johnston N, Erwin P, Crowe P, Fernig DG, Campbell FC, Anderson IP, Rudland PS, El-Tanani MK: RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene. 2008, Sep 15.,

Title: Osteopontin: a new role for a familiar actor
Authors: Nicholas IF Johnston
Mohamed K El-Tanani
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 6/2008
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2199

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2008

Eph receptors in breast cancer: roles in tumor promotion and tumor suppression

Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda

The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines

Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer